NFE2L2 and pancreatic neoplasm: These findings demonstrated that brusatol inhibits gemcitabine-induced Nrf2 activation through reducing the expression of Nrf2 protein in pancreatic cancer cells and that brusatol might intensify the anticancer effects of gemcitabine in pancreatic cancer cells.